1. Home
  2. TSN vs RPRX Comparison

TSN vs RPRX Comparison

Compare TSN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyson Foods Inc.

TSN

Tyson Foods Inc.

HOLD

Current Price

$64.20

Market Cap

21.6B

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$48.04

Market Cap

19.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSN
RPRX
Founded
1935
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Meat/Poultry/Fish
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6B
19.5B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
TSN
RPRX
Price
$64.20
$48.04
Analyst Decision
Buy
Strong Buy
Analyst Count
10
4
Target Price
$66.90
$50.00
AVG Volume (30 Days)
2.4M
2.8M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
3.11%
1.96%
EPS Growth
N/A
N/A
EPS
0.24
1.78
Revenue
$54,441,000,000.00
$2,378,193,000.00
Revenue This Year
$5.63
$38.30
Revenue Next Year
$1.13
$4.80
P/E Ratio
$272.88
$26.88
Revenue Growth
2.12
5.06
52 Week Low
$50.56
$31.58
52 Week High
$66.24
$49.06

Technical Indicators

Market Signals
Indicator
TSN
RPRX
Relative Strength Index (RSI) 55.85 59.71
Support Level $61.99 $35.32
Resistance Level $64.93 $49.06
Average True Range (ATR) 1.23 0.94
MACD 0.27 0.02
Stochastic Oscillator 77.89 73.40

Price Performance

Historical Comparison
TSN
RPRX

About TSN Tyson Foods Inc.

Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, composing about 40% and 30% of sales, respectively. Prepared foods constituted 18% of fiscal 2025 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: